Circadian‑Timed OSK mRNA Delivery Enhances Mitochondrial Rejuvenation While Limiting Dedifferentiation Risk
Hypothesis
Transient OSK mRNA delivery administered at the onset of the active phase of the circadian cycle improves mitochondrial function and epigenetic age reversal more effectively than delivery at rest, without increasing markers of dedifferentiation or tumorigenic risk.
Mechanistic Rationale
The NAD+ salvage enzyme NAMPT exhibits a circadian rhythm, peaking during the early active phase in mouse liver and muscle. Elevated NAD+ boosts SIRT1 deacetylase activity, which promotes chromatin relaxation and facilitates OSK‑driven demethylation of age‑associated loci. Simultaneously, SIRT1 activates PGC‑1α, stimulating mitochondrial biogenesis and ROS detoxification. By aligning OSK expression with this NAD+ surge, the reprogramming factors encounter a cellular environment primed for both epigenetic reset and metabolic upgrade, reducing the need for prolonged expression that could push cells toward pluripotency.
Predictions and Experimental Design
- Treatment groups – Aged (24‑month) mice receive lipid‑nanoparticle‑encapsulated OSK mRNA either at ZT4 (early active) or ZT16 (early rest) for three weekly cycles (2 h pulse each). Controls receive empty LNPs.
- Readouts – After four weeks:
- Mitochondrial respiration measured by Seurat OCR in isolated hepatocytes and skeletal muscle.
- Epigenetic age assessed using liver and blood DNA methylation clocks.
- Pluripotency marker levels (Oct4, Nanog, Sox2) quantified by qPCR and immunostaining.
- Senescence burden (p16^Ink4a, SA‑β‑gal) and fibrosis markers evaluated.
- Tumor incidence monitored over six months.
- Expected outcome – The ZT4 group shows a significant increase in OCR (≈30 % versus control), a measurable reduction in epigenetic age (≈1.5 years), baseline levels of Oct4/Nanog, reduced fibrosis and senescence, and no rise in tumor formation. The ZT16 group displays modest or no improvement, similar to controls.
Potential Outcomes and Falsifiability
If the ZT4 regimen fails to produce superior mitochondrial or epigenetic benefits compared to ZT16 or control, the hypothesis is falsified. Conversely, detection of elevated Oct4/Nanog or tumor formation specifically in the ZT4 arm would indicate that circadian timing exacerbates dedifferentiation risk, also refuting the claim. A neutral result (no difference between timings) would similarly reject the proposed mechanistic link.